You Started a GLP-1. Now the Real Question Is: What Are You Losing?

By Dr. Ashley Katzenback, PT, DPT | Cape Concierge Physical Therapy

The number on the scale is going down. The medication is working exactly as advertised. And yet, if no one on your care team has talked to you about what else might be happening inside your body right now — you're getting incomplete care.

This isn't a scare piece about GLP-1 medications. Semaglutide, tirzepatide, and their counterparts represent a genuine breakthrough in metabolic medicine, and for many women, the benefits are real and meaningful. But a prescription is not a plan. And the gap between what the medication does and what your body actually needs to thrive long-term is exactly where most patients are left on their own.

Let's talk about what's actually at stake — and why it matters not just today, but twenty years from now.

The Weight Loss You Don't See Coming

When GLP-1 medications work, they work dramatically. Clinical trials show mean weight reductions of 13–22% of body weight, depending on the drug and dose. What those headline numbers don't tell you is what kind of weight is being lost.

A 2025 DXA substudy of tirzepatide (the SURMOUNT-1 trial) found that participants lost 10.9% of total lean mass over 72 weeks. Research from UC Davis estimates that roughly 20% of the weight lost on GLP-1 therapy is MUSCLE MASS— a proportion comparable to other aggressive calorie-restriction approaches.

Read that again: up to one-fifth of what you're losing isn't fat. It's muscle.

For a woman in her 40s or 50s who is already navigating the hormonal transitions of perimenopause — when estrogen's role in muscle protein synthesis and neuromuscular signaling is already declining — this isn't a side note. It's a central clinical concern.

Why Muscle Loss Is Not a Cosmetic Issue

Sarcopenia — the progressive loss of skeletal muscle mass and function — begins as early as age 30, with adults losing an average of 3–8% of muscle mass per decade. After 60, that rate accelerates to more than 1% per year without intervention.

The downstream consequences are not subtle:

• Sarcopenia is strongly associated with increased fall risk, fracture risk, and loss of independence.

• Decreased muscle mass is a risk factor for loss of independence in patients over 90 — which means the decisions you make in your 40s and 50s are writing that story right now.

• Muscle weakness, impaired balance, and reduced proprioceptive function compound each other over time, creating a feedback loop that is far harder to reverse than it is to prevent.

Think of it this way: your muscle mass is your structural insurance policy. Every year you maintain it, you're paying the premium on your future independence. Every year it erodes unchecked — whether from age, inactivity, caloric restriction, or GLP-1-driven weight loss — you're letting that policy lapse.

The Bone Density Problem We Talk About Every Day!

If the muscle story gets limited attention, the bone story gets almost none.

A 2024 randomized controlled trial by Hansen et al., published in eClinicalMedicine, found that 52 weeks of once-weekly semaglutide reduced hip bone mineral density by 2.6% and lumbar spine bone density by 2.1% compared to placebo — with increased bone resorption and no compensatory increase in bone formation.

The mechanism matters here: when body weight decreases rapidly, the mechanical load on bone decreases with it. Bone responds to the forces placed on it — that's how it maintains density. Remove the load, and bone resorption outpaces formation. Add in the bone-demineralizing effects of cortisol dysregulation (common in women under chronic stress) and the estrogen decline of perimenopause, and you have a compounding picture that no one is connecting the dots on.

Critically, a 2024 secondary analysis published in JAMA Network Open found that the combination of exercise and GLP-1 therapy fully preserved hip, spine, and forearm bone mineral density — even with greater total weight loss than the medication-alone group. GLP-1 therapy alone reduced BMD. GLP-1 plus exercise did not. This is so exciting and meaningful for what we are trying to change everyday at Cape Concierge Physical Therapy.

When Muscle and Bone Loss Converge: Osteosarcopenia

When low muscle mass and low bone density occur together — which they increasingly do in women navigating midlife — the clinical picture shifts from manageable to serious.

Osteosarcopenia (yes this is a real word!) is not merely the sum of two separate problems. Research shows that women with both conditions face significantly higher risk for frailty, falls, fractures, increased morbidity, and mortality than those with either condition alone. Bone and muscle communicate through mechanical and biochemical pathways; when both are compromised, the whole system becomes fragile in ways that are difficult to reverse.

This is what frailty actually looks like in clinical practice — not frailty as an abstract concept, but as the lived experience of a woman in her 70s who can no longer get up from the floor, recover from a stumble, or tolerate the physical demands of an acute illness. The trajectory toward that outcome doesn't start at 75. It starts NOW, with the choices being made about weight loss, muscle preservation, and bone loading in the decades before.

What the Prescription Doesn't Include

Here is the honest clinical picture: GLP-1 medications are not designed to preserve muscle mass. They are not designed to protect bone density. They don't optimize protein intake, coach you through resistance training, assess your pelvic floor as your body changes, or address the psychological complexity of a body in rapid transformation.

That's not a criticism of the medication. It's a description of what it is — and what it isn't.

What your body actually needs alongside GLP-1 therapy:

Adequate protein, aggressively prioritized. Research consistently shows that higher protein intake during caloric restriction mitigates lean mass loss. This isn't "eat more protein." It's a clinical target — typically 1.2–1.6g per kilogram of body weight — that requires intentional nutritional strategy, not generic advice.

Resistance training, not optional. The JAMA Network Open bone density data is clear: exercise is the intervention that preserved bone during GLP-1-driven weight loss. Resistance training also stimulates muscle protein synthesis, helps maintain fast-twitch fiber function, and provides the mechanical loading that bone needs to stay dense. T

Pelvic floor awareness. Rapid changes in body weight, core muscle mass, and intra-abdominal pressure affect pelvic floor function in ways that are rarely discussed. A body in transformation is a pelvic floor under new demands.

Movement assessment and monitoring. You cannot manage what you don't measure. Tracking lean mass, strength benchmarks, and functional movement patterns throughout GLP-1 therapy gives you actionable data — not just a number on a scale. A Kinotek Movement Physical, Grip Strength, and lean muscle measurement are simple ways to monitor progress.

Behavioral and hormonal context. Food is not just fuel. The appetite suppression that GLP-1 medications produce can be disorienting, triggering complex emotions around eating, identity, and body image that deserve real clinical support — not just a follow-up appointment six months out.

The Window You Have Right Now

Here's what the research makes clear: the musculoskeletal effects of GLP-1 therapy are not inevitable. They are the default outcome of taking the medication without a support plan — and they are largely preventable with the right interventions applied from the beginning.

The window matters. Bone and muscle respond to intervention. A woman who begins resistance training, prioritizes protein, and monitors her musculoskeletal health before or concurrent with starting a GLP-1 will have a fundamentally different body composition outcome than a woman who waits until she notices a problem.

This is what "education as an intervention" means in practice. Not information for its own sake — but clinical knowledge applied at the right moment, before the crisis, to change the trajectory.

You Deserve a Team, Not a Prescription

At Cape Concierge Physical Therapy, we built our GLP-1 Coaching Program precisely because this gap is real and the consequences are long-term. Your team — Physical Therapist, Strength Coach, Nutritionist, Pelvic Health Specialist, GYN, and Psychiatric NP — coordinates around the clinical realities of what GLP-1 therapy actually does to a woman's body.

This is not reactive medicine. It is not one-size-fits-all. It is the support the prescription never came with — because your future mobility, independence, and strength are worth planning for now.

Cape Concierge Physical Therapy serves women across Cape Cod, and Plymouth, with concierge-model physical therapy, pelvic health, and preventative care. Learn more at capeconciergept.com or contact us to schedule a discovery call.